Thomas Smith
Stock Analyst at Leerink Partners
(1.99)
# 3,153
Out of 5,090 analysts
60
Total ratings
31.48%
Success rate
7.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Initiates: Outperform | $42 | $21.94 | +91.43% | 1 | Dec 1, 2025 | |
| RAPT RAPT Therapeutics | Upgrades: Outperform | $16 → $37 | $34.30 | +7.89% | 3 | Sep 26, 2025 | |
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $0.88 | +13.53% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $3.32 | +171.08% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $2.96 | +136.89% | 7 | Nov 19, 2024 | |
| ALMS Alumis | Initiates: Outperform | $29 | $11.04 | +162.68% | 1 | Jul 23, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $6.93 | +462.77% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $6.37 | +308.16% | 1 | Mar 25, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $113.99 | -82.45% | 1 | Nov 14, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $903.14 | -51.83% | 3 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $93.39 | -61.45% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $2.46 | +184.55% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $22.88 | -8.22% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $32.16 | +39.93% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $13.50 | -55.56% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $5.69 | +5.54% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $0.68 | +635.84% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $14.98 | +13.48% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $29.25 | +118.84% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $17.02 | +311.28% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $1.61 | +1,514.91% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $39.00 | -69.23% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $27.16 | +1,372.75% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $21.88 | +265.63% | 2 | Dec 8, 2020 |
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $42
Current: $21.94
Upside: +91.43%
RAPT Therapeutics
Sep 26, 2025
Upgrades: Outperform
Price Target: $16 → $37
Current: $34.30
Upside: +7.89%
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $0.88
Upside: +13.53%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $3.32
Upside: +171.08%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $2.96
Upside: +136.89%
Alumis
Jul 23, 2024
Initiates: Outperform
Price Target: $29
Current: $11.04
Upside: +162.68%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $6.93
Upside: +462.77%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $6.37
Upside: +308.16%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $113.99
Upside: -82.45%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $903.14
Upside: -51.83%
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $93.39
Upside: -61.45%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $2.46
Upside: +184.55%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $22.88
Upside: -8.22%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $32.16
Upside: +39.93%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $13.50
Upside: -55.56%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $5.69
Upside: +5.54%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $0.68
Upside: +635.84%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $14.98
Upside: +13.48%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $29.25
Upside: +118.84%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $17.02
Upside: +311.28%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $1.61
Upside: +1,514.91%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $39.00
Upside: -69.23%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $27.16
Upside: +1,372.75%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $21.88
Upside: +265.63%